Smartleaf Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Smartleaf Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.93K	Hold	726	–	–	﹤0.01%	2542
2026 Q1	$6.86K	Sell	726 -229	-24%	-$1.78K	﹤0.01%	2503
2025 Q4	$7.32K	Buy	955 +17	+2%	+$123	﹤0.01%	2531
2025 Q3	$7.08K	Buy	938 +647	+222%	+$5.39K	﹤0.01%	2249
2025 Q2	$2.72K	Buy	291 +203	+231%	+$1.89K	﹤0.01%	2245
2025 Q1	$691	Sell	88 -452	-84%	-$3.65K	﹤0.01%	2642
2024 Q4	$4.07K	Buy	540 +360	+200%	+$2.73K	﹤0.01%	2324
2024 Q3	$1.37K	Buy	+180	New	+$1.37K	﹤0.01%	2586

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Smartleaf Asset Management's BCRX Position: Q2 2026 in Review

Smartleaf Asset Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 726 shares worth $6.93K. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

Smartleaf Asset Management first reported a position in BCRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.32K in Q4 2025. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Smartleaf Asset Management held 726 shares of BioCryst Pharmaceuticals worth $6.93K as of Q2 2026.
Smartleaf Asset Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2542 holding.
Smartleaf Asset Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Smartleaf Asset Management's BioCryst Pharmaceuticals position peaked at $7.32K in Q4 2025.
319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.